昂立教育:交大企管中心擬減持不超2%股份
格隆匯2月10日丨昂立教育(600661.SH)公佈,上海交大企業管理中心(以下簡稱“交大企管中心”)計劃以集中競價交易方式減持公司股份不超過573.0976萬股,即不超公司總股本的2%。
截止本公告日,交大企管中心及其一致行動人上海交大產業投資管理(集團)有限公司(以下簡稱“交大產業集團”)分別持有昂立教育2135.27萬股(其中274.72萬股為認購公司2015年度非公開發行的股份)、3476.82萬股(其中274.72萬股為認購公司2015年度非公開發行的股份),合計持有5612.096萬股,佔公司總股本的19.59%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.